What Biopharmaceutical and Medical Device Companies Need to Know About Telemedicine and Patient Care

Addressing Challenges and Mitigating Risks During the COVID-19 Pandemic and Beyond

Wednesday, June 3, 2020
12:00–1:00 PM ET
Arnold & Porter Webinar Series: Pharma 3.0

The third webinar in our series on "Addressing Challenges and Mitigating Risks During the COVID-19 Pandemic and Beyond" will address:

  • Basic regulatory framework governing telehealth

    • State
    • Licensure laws
    • Telehealth laws
    • Corporate practice of medicine
    • Coverage and reimbursement
  • Federal

    • Coverage and reimbursement
  • Categories of regulatory waivers instituted for public health emergency
  • Privacy and cybersecurity considerations

    • Pre-COVID-19
    • In response to COVID-19
  • Hypothetical—A pharmaceutical company partners with a telehealth company (with and without a contracted pharmacy)

About the Webinar Series

Life sciences companies are doing their best to conduct business through remote customer interactions, and many expect that the expanded use of such technologies will persist well beyond the current crisis. While the life sciences industry can address many healthcare practitioner (HCP) and patient needs in this manner, the general rules, guidances and codes governing such interactions were not necessarily written with remote interactions in mind. Thus, enforcement risks may emerge in the absence of careful planning and strong safeguards.

Our webinar series will delve into these issues to (1) identify the potential legal, regulatory and compliance risks, and (2) provide practical considerations for planning and successful implementation.

Meet the speakers

Email Disclaimer